BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 11, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Sept. 1, 2021

Sep. 1, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, ANI, Genhouse, Gloria, Huya, Innocare, Jazz, Ligand, Medipharm, Medivir, Merz.
Read More

Regulatory actions for Aug. 24-30, 2021

Aug. 31, 2021
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Antengene, Astrazeneca, Beigene, Biontech, Celltrion, Enzene, Exelixis, Glaxosmithkline, Junshi, Kalvista, Laekna Therapeutics Shanghai, Merck, Moderna, Ono, Pfizer, RDIF, Roche, Takeda, Tonix, Valneva, Vir, Zogenix, Zydus Cadila.
Read More

Regulatory actions for Aug. 31, 2021

Aug. 31, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Mirus.
Read More

Regulatory actions for Aug. 31, 2021

Aug. 31, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advaccine, Anixa, Diffusion, Epygenix, Inovio, Junshi, Lantern, Octapharma, Polaryx, Poseida, Therapeutic Solutions, UCB.
Read More

Regulatory actions for Aug. 30, 2021

Aug. 30, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Impedimed, Phase Scientific, Vapotherm, Visby Medical.
Read More

Regulatory actions for Aug. 30, 2021

Aug. 30, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Biomarin, Enzene, Incyte, Junshi, Laekna, Morphosys, Pendopharm, Roche.
Read More

Regulatory actions for Aug. 27, 2021

Aug. 27, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Becton Dickinson, Microtransponder.
Read More

Regulatory actions for Aug. 27, 2021

Aug. 27, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Ascendis, Astrazeneca, Biocryst, Biontech, Exelixis, Ironwood, Marinus, Merck, Ono, Pfizer, Scancell, Servier, Sesen, Takeda, Vertex, Zogenix.
Read More

Regulatory actions for Aug. 26, 2021

Aug. 26, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Fuse Medical, FX Shoulder, Thermo Fisher.
Read More

Regulatory actions for Aug. 26, 2021

Aug. 26, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aerami, Argenx, Blade, CTI, Moderna, RDIF, Taysha.
Read More
Previous 1 2 … 230 231 232 233 234 235 236 237 238 … 337 338 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Neurology illustration

    Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

    BioWorld
    Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing